Durable complete response of hepatocellular carcinoma after metronomic capecitabine

被引:13
作者
Brandi, Giovanni [1 ]
de Rosa, Francesco [1 ]
Bolondi, Luigi [2 ]
Agostini, Valentina [1 ]
Di Girolamo, Stefania [1 ]
Nobili, Elisabetta [1 ]
Biasco, Guido [1 ]
机构
[1] Univ Bologna, Dept Hematol & Oncol Sci L E A Seragnoli, Policlin St Orsola Malpighi, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Internal Med, Policlin St Orsola Malpighi, I-40138 Bologna, Italy
关键词
hepatocellular carcinoma; metronomic chemotherapy; capecitabine; antiangiogenic therapy; PHASE-II; CHEMOTHERAPY;
D O I
10.1177/548.6527
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Hepatocellular carcinoma (HCC) is a highly vascular tumor which is poorly responsive to standard systemic chemotherapy. Recently, various antiangiogenic targeted agents have shown promising activity at different levels of evidence in patients with advanced HCC, suggesting that such treatments might be effective. Case report. Since chemotherapy administered with metronomic schedules inhibits angiogenesis, we treated a 64-year-old man with advanced HCC with metronomic capecitabine. After only two months of treatment the HCC nodules disappeared on ultrasonography. This finding was confirmed by a computed tomography scan. After more than three years the patient is still in treatment with minimal toxicity and maintains a complete remission. Conclusions. Our case report suggests that metronomic capecitabine may be effective in advanced HCC patients while being also well tolerated. This is important, given the frequent comorbidities of HCC patients. Free full text available at www.tumorionline.it
引用
收藏
页码:1028 / 1030
页数:3
相关论文
共 13 条
[1]   Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial [J].
Boige, V. ;
Raoul, J-L ;
Pignon, J-P ;
Bouche, O. ;
Blanc, J-F ;
Dahan, L. ;
Jouve, J-L ;
Dupouy, N. ;
Ducreux, M. .
BRITISH JOURNAL OF CANCER, 2007, 97 (07) :862-867
[2]  
BRANDI G, 2010, ASCO 2010 GASTR CANC
[3]  
BRANDI G, 2007, ILCA ANN C 2007
[4]   Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum [J].
Burroughs, A ;
Hochhauser, D ;
Meyer, T .
LANCET ONCOLOGY, 2004, 5 (07) :409-418
[5]   Five years of clinical experience with metronomic chemotherapy: Achievements and perspectives [J].
Emmenegger, Urban ;
Kerbel, Robert S. .
ONKOLOGIE, 2007, 30 (12) :606-608
[6]   Significance of circulating endothelial progenitor cells in hepatocellular carcinoma [J].
Ho, Joanna W. Y. ;
Pang, Roberta W. C. ;
Lau, Cecilia ;
Sun, Chris K. ;
Yu, Wan Ching ;
Fan, Sheung Tat ;
Poon, Ronnie T. P. .
HEPATOLOGY, 2006, 44 (04) :836-843
[7]   The anti-angiogenic basis of metronomic chemotherapy [J].
Kerbel, RS ;
Kamen, BA .
NATURE REVIEWS CANCER, 2004, 4 (06) :423-436
[8]   Sorafenib in advanced hepatocellular carcinoma [J].
Llovet, Josep M. ;
Ricci, Sergio ;
Mazzaferro, Vincenzo ;
Hilgard, Philip ;
Gane, Edward ;
Blanc, Jean-Frederic ;
Cosme de Oliveira, Andre ;
Santoro, Armando ;
Raoul, Jean-Luc ;
Forner, Alejandro ;
Schwartz, Myron ;
Porta, Camillo ;
Zeuzem, Stefan ;
Bolondi, Luigi ;
Greten, Tim F. ;
Galle, Peter R. ;
Seitz, Jean-Francois ;
Borbath, Ivan ;
Haussinger, Dieter ;
Giannaris, Tom ;
Shan, Minghua ;
Moscovici, Marius ;
Voliotis, Dimitris ;
Bruix, Jordi .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390
[9]   Redefining the target: Chemotherapeutics as antiangiogenics [J].
Miller, KD ;
Sweeney, CJ ;
Sledge, GW .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :1195-1206
[10]   Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma [J].
Park, SH ;
Lee, Y ;
Han, SH ;
Kwon, SY ;
Kwon, OS ;
Kim, SS ;
Kim, JH ;
Park, YH ;
Lee, JN ;
Bang, SM ;
Cho, EK ;
Shin, BD ;
Lee, JH .
BMC CANCER, 2006, 6 (1)